查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1924731

Pomalidomide膠囊市場按規格、適應症、治療線和通路- 全球預測 2026-2032

Pomalidomide Capsules Market by Strength, Indication, Treatment Line, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Pomalidomide膠囊市場價值將達到 10.6 億美元，到 2026 年將成長至 11.5 億美元，到 2032 年將達到 20.1 億美元，年複合成長率為 9.55%。

關鍵市場統計數據
基準年 2025 10.6億美元
預計年份：2026年 11.5億美元
預測年份 2032 20.1億美元
複合年成長率 (%) 9.55%

針對醫療機構中Pomalidomide膠囊的臨床定位、相關人員影響和營運考慮進行策略概述

Pomalidomide膠囊已成為血液腫瘤治療領域的重要選擇，尤其適用於治療方案複雜、需要安全性良好且療效確切的口服藥物的情況。本概要總結了Pomalidomide的臨床應用依據、其與其他治療藥物的定位，以及商業性和臨床相關人員在將其納入治療流程時應考慮的策略因素。下文將基於真實世界的處方模式進行實證分析，重點闡述其對藥學委員會、醫院藥屋主任和專科藥品經銷商的實際意義。

揭示臨床實踐、監管應對措施和獲取模式的變革性變化，以重塑泊Pomalidomide膠囊的處方和給藥方式

在臨床創新、監管調整和治療模式演變的推動下，Pomalidomide膠囊的治療和商業性格局正在經歷變革性變化。近期臨床試驗結果和真實世界證據正在加深我們對Pomalidomide潛在價值的理解，促使臨床醫生重新評估治療順序策略，並探索能夠在延長療效的同時控制毒性的新型組合方案。

檢驗2025年美國關稅調整對口服抗癌產品的供應、採購和取得的累積營運和商業影響

美國於2025年實施的新關稅對透過全球分銷網路運輸的藥品供應鏈和商業性活動產生了顯著影響。對於一家口服抗癌藥物的生產商和經銷商，關稅帶來的成本壓力迫使其重新評估籌資策略、貨運路線以及與第三方物流供應商的合約條款。因此，採購團隊優先考慮供應鏈的韌性和供應商多元化，以確保供應的連續性免受關稅波動的影響。

詳細的細分資訊揭示了劑量、適應症、通路和治療方案如何相互作用，從而影響臨床應用和商業策略。

市場區隔分析揭示了一些微妙的模式，相關人員在對Pomalidomide膠囊進行治療和商業性定位時應考慮這些模式。按劑型分類，市場分析涵蓋 1 毫克、2 毫克、3 毫克和 4 毫克四種規格，這些劑量方案會影響處方柔軟性、毒性管理和依從性。臨床醫師傾向於選擇較低劑量來調整合併症患者的治療方案，而較高劑量則在既定的劑量方案中發揮重要作用，以實現對疾病的有效控制。

全面的區域情報突顯了美洲、歐洲、中東和非洲以及亞太地區如何對藥品取得、報銷和分銷產生不同的影響。

區域趨勢對Pomalidomide膠囊在不同醫療保健系統中的引入、報銷和分發方式有顯著影響。在美洲，集中式支付系統和私人保險並存，導致獲取途徑多樣化，這就要求生產商制定全國性的合約策略和社區患者援助計劃。法規環境強調核准後證據的收集，而臨床實踐模式則傾向於由多學科腫瘤委員會來制定治療順序決策。

推動Pomalidomide領域成功商業化、證據產生和生命週期規劃的關鍵公司層面趨勢和策略性舉措

Pomalidomide市場的企業活動反映了臨床投資、生命週期管理和商業性夥伴關係的整合。專注於口服腫瘤藥物的主要企業通常會將強大的臨床開發項目與有針對性的真實世界證據產生相結合，以支持適應症擴展和與支付方的談判。與專科經銷商和藥品福利管理機構的策略聯盟能夠建構整合的患者支持生態系統，從而解決用藥依從性、毒性管理和報銷協助等問題。

為實現持續推廣，經營團隊可採取切實可行的策略要務，加強證據支持、增強供應韌性、倡導病患權益、促進支付方參與。

產業領導者應採取一系列切實有效、影響深遠的措施，以確保Pomalidomide膠囊在臨床上的應用，維持藥物可近性，並最佳化供應穩定性。應優先考慮整合證據策略，將隨機試驗結果與真實世界數據結合，以證明其在預期適應症和治療方案中的療效。這種方法將增強向支付方論證其價值，並透過將數據轉化為可操作的治療指南來支持臨床實踐。

我們採用透明的混合方法調查方法，結合文獻綜合、相關人員訪談和情境分析，以確保研究結果的穩健性和可重複性。

本報告的調查方法結合了對同行評審文獻、監管申報文件和臨床試驗註冊數據的系統性回顧，以及對臨床、支付方和分銷領域關鍵相關人員的重點一手調查。資料收集著重於近期臨床試驗結果、上市後警戒調查結果和監管標籤變更記錄。一手訪談補充了二手研究結果，捕捉了醫院藥劑師、專科藥房經理和腫瘤藥物商業負責人的運作細節。

簡明扼要地總結了臨床、運作和可近性方面的必要因素，這些因素將決定泊Pomalidomide膠囊的持續應用和患者可近性。

Pomalidomide膠囊在血液腫瘤學領域佔據著獨特且不斷發展的地位，這得益於臨床證據支持其用於某些晚期治療適應症，以及強調患者權益和供應鏈完整性的商業性實踐。更廣泛的格局反映了證據生成、監管行動和支付方決策之間日益加速的相互作用，這些因素共同塑造著製造商和醫療服務提供者的准入途徑和營運重點。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Pomalidomide膠囊市場（依規格）

  • 1mg
  • 2mg
  • 3mg
  • 4mg

第9章Pomalidomide膠囊市場依適應症分類

  • 多發性骨髓瘤
  • 骨髓發育不良症候群

第10章Pomalidomide膠囊市場，依治療線分類

  • 二級治療
  • 三級治療

第11章Pomalidomide膠囊市場（依通路分類）

  • 線上
  • 離線

第12章Pomalidomide膠囊市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章Pomalidomide膠囊市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國泊Pomalidomide膠囊市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國Pomalidomide膠囊市場

第16章：中國Pomalidomide膠囊市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Admac Pharma Limited
  • Alkem Laboratories Limited
  • Amerigen Life Sciences LLP
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Celgene Corporation
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • EBIO Global Trade LLP
  • Encore Healthcare Private Limited
  • Glenmark Pharmaceuticals Limited
  • Hetero Healthcare Limited
  • Intas Pharmaceuticals Limited
  • Natco Pharma Limited
  • Pharmalink Laboratories Private Limited
  • Sandoz AG
  • Shree Lokanath Pharmaceuticals Private Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-7A380DA7C45F

The Pomalidomide Capsules Market was valued at USD 1.06 billion in 2025 and is projected to grow to USD 1.15 billion in 2026, with a CAGR of 9.55%, reaching USD 2.01 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.06 billion
Estimated Year [2026] USD 1.15 billion
Forecast Year [2032] USD 2.01 billion
CAGR (%) 9.55%

A strategic introduction synthesizing clinical positioning, stakeholder implications, and operational considerations for pomalidomide capsules across healthcare settings

Pomalidomide capsules have emerged as a critical therapeutic agent in hematology-oncology, especially where complex treatment sequences demand oral agents with manageable safety profiles and proven efficacy. This executive overview synthesizes the clinical rationale behind pomalidomide use, its positioning relative to other therapeutic classes, and the strategic levers that commercial and clinical stakeholders must consider when integrating this agent into treatment algorithms. The content that follows emphasizes actionable implications for formulary committees, hospital pharmacy directors, and specialty distributors while maintaining an evidence-informed lens on real-world practice patterns.

Clinical adoption of pomalidomide reflects a convergence of improved patient tolerability, oral administration convenience, and evolving evidence in later-line indications. Translational insights from recent studies underscore how dosing flexibility and combination regimens influence both care delivery and prescriber preference. Consequently, decision-makers must weigh clinical merits alongside supply chain considerations, reimbursement dynamics, and patient access pathways. By framing pomalidomide capsules within these intersecting dimensions, the introduction sets the stage for deeper analysis of landscape shifts, tariff impacts, segmentation nuances, regional differentials, and corporate strategy implications presented in subsequent sections.

Unpacking the transformative shifts in clinical practice, regulatory action, and access models reshaping how pomalidomide capsules are prescribed and delivered

The therapeutic and commercial landscape for pomalidomide capsules is undergoing transformative shifts driven by clinical innovation, regulatory adaptations, and evolving treatment paradigms. Recent clinical trial results and real-world evidence have expanded the understanding of where pomalidomide delivers the most value, prompting clinicians to reassess sequencing strategies and to consider novel combination regimens that can extend efficacy while managing toxicity.

Concurrently, regulatory pathways and label updates are shortening the time between clinical insight and formulary impact, which places a premium on agile medical affairs and evidence generation teams. Observational data and post-marketing surveillance have sharpened the safety profile, reinforcing the importance of structured monitoring protocols in hospital pharmacy settings. Payers are responding to these clinical developments by refining coverage criteria and utilization management approaches, which in turn affects how manufacturers and distributors engage with stakeholders.

Market access and commercialization are also being reshaped by patient-centric models that prioritize adherence and continuity of care; oral oncology agents like pomalidomide require integrated support programs, including adherence counseling and side-effect mitigation services. Finally, cross-sector collaboration between clinical investigators, regulatory affairs, and supply chain partners is becoming essential to manage product availability and to optimize treatment pathways across diverse practice environments.

Examining the cumulative operational and commercial consequences of United States tariff adjustments in 2025 on supply, procurement, and access for oral oncology products

The imposition of new tariff measures in the United States in 2025 introduced discrete supply chain and commercial implications for pharmaceutical products transported through global distribution networks. For manufacturers and distributors of oral oncology agents, these tariff-driven cost pressures necessitated a reevaluation of sourcing strategies, freight routing, and contractual terms with third-party logistics providers. As a result, procurement teams prioritized supply chain resilience and supplier diversification to insulate supply continuity from tariff-induced volatility.

Clinicians and hospital pharmacies experienced indirect effects as procurement cycles lengthened and tender negotiations incorporated incremental duties and customs complexities. Contract administrators renegotiated clauses related to landed cost and delivery timelines, and some organizations expanded local warehousing capacity to mitigate transit disruptions. Parallel to these operational adjustments, payer contracting teams revisited formulary placement strategies to reflect changes in acquisition cost structures and to negotiate risk-sharing agreements that could offset temporary price pressure.

Pharmaceutical companies responded by accelerating nearshoring and dual-sourcing initiatives where feasible, and by engaging in proactive regulatory and customs planning to secure preferential treatment where legitimate tariff exemptions applied. The aggregate of these responses strengthened supply chain agility and highlighted the importance of scenario planning in commercial operations, while reinforcing the need for transparent dialogue among manufacturers, distributors, and payers to preserve patient access during periods of trade-induced cost fluctuation.

Detailed segmentation intelligence revealing how dosing, indication, distribution channel, and line of therapy interact to shape clinical use and commercial strategy

Segmentation insights reveal nuanced patterns that stakeholders must consider when positioning pomalidomide capsules across therapeutic and commercial dimensions. Based on Strength, market is studied across 1 Mg, 2 Mg, 3 Mg, and 4 Mg, and these dose formulations inform prescribing flexibility, toxicity management, and adherence considerations; clinicians often select lower strengths to titrate therapy in patients with comorbidities, while higher strengths play a role in established dosing regimens for robust disease control.

Based on Indication, market is studied across Multiple Myeloma and Myelodysplastic Syndrome, and the distinct clinical pathways for these indications create differentiated demand profiles. In Multiple Myeloma, pomalidomide has a central role in later-line combination strategies, influencing patient support needs and specialty pharmacy engagement. In Myelodysplastic Syndrome, the therapeutic rationale requires careful hematologic monitoring and collaboration between oncology and hematology services to optimize outcomes.

Based on Distribution Channel, market is studied across Hospital Pharmacy and Retail Pharmacy, and distribution choice affects inventory governance, reimbursement interactions, and patient counseling practices. Hospital pharmacies manage inpatient and outpatient oncologic care continuity, whereas retail specialty pharmacies often provide enhanced medication access programs and adherence services. Based on Treatment Line, market is studied across Second Line and Third Or Later Line, and treatment-line segmentation drives clinical expectation setting, payer negotiation dynamics, and the design of promotional and educational initiatives targeted at prescribers and multidisciplinary care teams.

Taken together, these segmentation lenses offer a multidimensional view of how formulation, indication, distribution, and treatment sequencing intersect to shape utilization patterns, clinical workflows, and commercial tactics. Understanding these intersections allows stakeholders to craft differentiated value propositions for each clinical and distribution scenario.

Comprehensive regional intelligence highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific differentially influence access, reimbursement, and distribution

Regional dynamics exert a strong influence on how pomalidomide capsules are adopted, reimbursed, and distributed across diverse healthcare systems. In the Americas, centralized payer systems and private insurance coexist, creating heterogeneous access pathways that require manufacturers to deploy both national contracting strategies and localized patient support programs. The regulatory environment emphasizes post-authorization evidence collection, and clinical practice patterns favor multidisciplinary tumor boards that shape therapeutic sequencing decisions.

Europe, Middle East & Africa present a mosaic of regulatory frameworks and reimbursement philosophies where national health technology assessment outcomes and local budgetary constraints can significantly affect uptake. Stakeholders operating in this region often align clinical evidence generation with country-specific value dossiers and invest in health economics and outcomes research to demonstrate real-world benefit across payer segments. Supply chain considerations vary widely, with some markets requiring dedicated cold chain or controlled distribution infrastructure and others necessitating targeted educational outreach to hematology specialists.

Asia-Pacific encompasses both advanced markets with established specialty pharmacy networks and emerging markets with evolving oncology care capacity. Regulatory timelines and importation policies differ, prompting tailored launch sequencing and phased market entry strategies. In many Asia-Pacific markets, co-pay structures and out-of-pocket dynamics shape patient access, making patient assistance programs and locally adapted adherence support essential. Across all regions, collaborative engagement with clinicians, payers, and pharmacy stakeholders remains critical to driving sustainable access and ensuring that clinical benefit translates into measurable patient outcomes.

Key company-level dynamics and strategic behavior that drive successful commercialization, evidence generation, and lifecycle planning in the pomalidomide sector

Corporate behavior in the pomalidomide landscape demonstrates a blend of clinical investment, lifecycle management, and commercial partnerships. Leading companies focused on oral oncology agents typically combine robust clinical development programs with targeted real-world evidence generation to support label expansion and payer discussions. Strategic alliances with specialty distributors and pharmacy benefit managers enable integrated patient support ecosystems that address adherence, toxicity management, and reimbursement navigation.

Operationally, vendors emphasize manufacturing quality controls and supply redundancy to minimize disruptions, while commercial teams prioritize tailored messaging to hematology-oncology centers and integrated delivery networks. R&D organizations invest in combination trials that pair pomalidomide with novel agents, seeking to enhance efficacy or reduce adverse event profiles. Simultaneously, market entrants and incumbents monitor patent landscapes and regulatory exclusivity timelines to inform lifecycle strategies, including potential formulation developments or differentiated support services.

Given the competitive and regulatory complexity of oncology therapeutics, companies that succeed tend to adopt cross-functional approaches that align clinical evidence, market access planning, and localized commercialization tactics. Executives must also balance short-term access objectives with long-term innovation planning to sustain therapeutic relevance and to respond to evolving standards of care.

Actionable strategic imperatives for executives to strengthen evidence, supply resilience, patient support, and payer engagement for sustained adoption

Industry leaders should adopt a set of pragmatic, high-impact actions to secure clinical adoption, preserve access, and optimize supply resilience for pomalidomide capsules. Prioritize integrated evidence strategies that marry randomized trial outcomes with real-world data to demonstrate comparative effectiveness across the intended indications and treatment lines. This approach strengthens value narratives for payers and supports clinical engagement by translating data into practical treatment guidance.

Enhance supply chain robustness by diversifying sourcing, implementing dual-sourcing where feasible, and increasing visibility across logistics pathways to anticipate and mitigate tariff or customs disruptions. Simultaneously, invest in scalable patient support programs that address adherence, toxicity management, and financial assistance, ensuring that oral delivery translates into sustained therapeutic continuity. Align commercial messaging to reflect segmentation realities-dose-specific clinical guidance, indication-based educational materials, and distribution-focused operational protocols-so that stakeholders receive targeted, pragmatic resources.

Finally, cultivate payer partnerships through outcomes-based contracting and evidence-sharing agreements that align reimbursement with real-world performance. Engage early with regional health authorities to understand reimbursement criteria and to adapt dossiers or health economic models to local expectations. By executing these prioritized actions, organizations can accelerate adoption, protect patient access, and build durable competitive differentiation in an evolving therapeutic landscape.

Transparent mixed-methods research approach combining literature synthesis, stakeholder interviews, and scenario analysis to ensure robust and reproducible insights

The research methodology underpinning this report combines a systematic review of peer-reviewed literature, regulatory filings, and clinical trial registries with targeted primary research among key stakeholders in clinical, payer, and distribution roles. Data collection emphasized contemporary clinical trial outcomes, post-marketing safety surveillance findings, and documented changes in regulatory labeling. Primary interviews supplemented secondary insights, capturing operational nuances from hospital pharmacists, specialty pharmacy managers, and commercial leaders engaged in oncology therapeutics.

Analytical methods included qualitative synthesis of therapeutic positioning, crosswalks between treatment-line protocols and distribution pathways, and scenario-based assessment of supply chain exposures to tariff dynamics. Consistency checks and triangulation were applied to reconcile variations across data sources and to validate interpretative conclusions. Where regional heterogeneity emerged, the methodology incorporated contextual adjustments to reflect local regulatory frameworks, reimbursement processes, and care delivery models.

The approach prioritized transparency and reproducibility, documenting source provenance for clinical and operational assertions and applying conservative interpretation where evidence was limited. This mixed-methods framework ensured that conclusions are grounded in both robust secondary evidence and the practical experience of frontline stakeholders.

Concise conclusion synthesizing clinical, operational, and access imperatives that determine sustainable adoption and patient access for pomalidomide capsules

Pomalidomide capsules occupy a distinct and evolving position within hematology-oncology, supported by clinical evidence that supports their use in specific later-line indications and by commercial practices that emphasize patient support and supply chain integrity. The broader landscape reflects accelerating interaction between evidence generation, regulatory action, and payer decision-making, which together shape access trajectories and operational priorities for manufacturers and healthcare providers.

Looking across segmentation and regional dimensions, successful deployment of pomalidomide requires nuanced alignment of dosing options with clinical workflows, distribution strategies tailored to hospital and retail channels, and localized market access approaches that resonate with national reimbursement frameworks. Operational resilience, particularly in the face of tariff-driven disruptions and shifting logistics dynamics, remains a critical determinant of uninterrupted patient access.

In sum, stakeholders who integrate rigorous evidence strategies with proactive supply and access planning will be best positioned to translate clinical benefit into routine, sustainable care delivery. These conclusions underscore the importance of cross-functional coordination and targeted investment to navigate the clinical and commercial complexities inherent to oral oncology therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pomalidomide Capsules Market, by Strength

  • 8.1. 1 Mg
  • 8.2. 2 Mg
  • 8.3. 3 Mg
  • 8.4. 4 Mg

9. Pomalidomide Capsules Market, by Indication

  • 9.1. Multiple Myeloma
  • 9.2. Myelodysplastic Syndrome

10. Pomalidomide Capsules Market, by Treatment Line

  • 10.1. Second Line
  • 10.2. Third Or Later Line

11. Pomalidomide Capsules Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Pomalidomide Capsules Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Pomalidomide Capsules Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pomalidomide Capsules Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Pomalidomide Capsules Market

16. China Pomalidomide Capsules Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Admac Pharma Limited
  • 17.6. Alkem Laboratories Limited
  • 17.7. Amerigen Life Sciences LLP
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Cadila Pharmaceuticals Limited
  • 17.10. Celgene Corporation
  • 17.11. Cipla Limited
  • 17.12. Dr. Reddy's Laboratories Limited
  • 17.13. EBIO Global Trade LLP
  • 17.14. Encore Healthcare Private Limited
  • 17.15. Glenmark Pharmaceuticals Limited
  • 17.16. Hetero Healthcare Limited
  • 17.17. Intas Pharmaceuticals Limited
  • 17.18. Natco Pharma Limited
  • 17.19. Pharmalink Laboratories Private Limited
  • 17.20. Sandoz AG
  • 17.21. Shree Lokanath Pharmaceuticals Private Limited
  • 17.22. Sun Pharmaceutical Industries Limited
  • 17.23. Teva Pharmaceutical Industries Ltd.
  • 17.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POMALIDOMIDE CAPSULES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POMALIDOMIDE CAPSULES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES POMALIDOMIDE CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA POMALIDOMIDE CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 1 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 1 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 1 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 2 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 2 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 2 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 3 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 3 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 3 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 4 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 4 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 4 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY THIRD OR LATER LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY THIRD OR LATER LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY THIRD OR LATER LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS POMALIDOMIDE CAPSULES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GCC POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GCC POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 85. GCC POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. GCC POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 87. GCC POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. G7 POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. G7 POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 100. G7 POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. G7 POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 102. G7 POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NATO POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NATO POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 105. NATO POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NATO POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 107. NATO POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES POMALIDOMIDE CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA POMALIDOMIDE CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 116. CHINA POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)